Drug Trial Radar · NCT00730964
A Prospective Surveillance Trial to Evaluate the Safety of Optison in Clinical Practice.
Last checked: Nov 20, 2026Latest source record: Jun 12, 2012 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
1,039
Actual
Start
May 2008
Primary completion
Oct 2009
Study completion Oct 2009
Sponsor
- Lead sponsor
- GE HealthcareIndustry
- Sponsor type
- Industry
- First posted
- Aug 8, 2008
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This prospective surveillance trial will gather safety information for Optison when it is used in routine practice.
Conditions
- Echocardiography
Interventions
Perflutren Protein-Type A Microspheres Injectable Suspension, United States Pharmacopeia (USP)Drug
The recommended dose of Optison is 0.5mL injected into a peripheral vein. This may be repeated for further contrast enhancement as needed. The injection rate should not exceed 1mL per second. Follow the Optison injection with a flush of 0.9% sodium chloride injection, USP or 5% dextrose in water injection, United States Pharmacopeia (USP) . The maximum total dose should not exceed 5.0mL in any 10 minutes period. The maximum total dose should not exceed 8.7mL in any one patient study.
Primary outcomes
What the sponsor says the trial is designed to measure.
- The Frequency of Serious Adverse Reactions (SAR)'s Among Subjects Who Receive Optison (Causally Related to the Product)During Contrast Enhanced Echocardiography in Routine Clinical Practice.Time frame: Within 24 hours post contrast administration
Locations
1 site in 1 country. Site status is shown where the registry gives one.
GE Healthcare
Princeton, New Jersey
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.